Cardio Diagnostics Holdings (CDIO) Change in Accured Expenses (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Change in Accured Expenses of $25528.0 for Q1 2026, up 147.9% sequentially from -$53292.0 in Q4 2025, and up 24.41% YoY from $20520.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Change in Accured Expenses for 5 years, with the latest figure at $25528.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 24.41% year-over-year to $25528.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14789.0 (up 112.69% YoY) and the FY2025 annual result came in at $9781.0, up 106.29% from the prior year.
- Change in Accured Expenses advanced to $25528.0 in Q1 2026 per CDIO's latest filing, from -$53292.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $482589.0 in Q2 2022 and troughed at -$379862.0 in Q4 2023.
- A 5-year average of -$45022.9 and a median of -$28340.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses sank 1430.18% in 2023, then soared 348.85% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$94956.0 in 2022, then slumped by 300.04% to -$379862.0 in 2023, then soared by 103.38% to $12853.0 in 2024, then sank by 514.63% to -$53292.0 in 2025, then surged by 147.9% to $25528.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $25528.0, -$53292.0, and $102010.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | 7,112.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7,112.00 |
| Jun 30, 2026 | 7,112.00 |
| Mar 31, 2026 | 25,528.00 |
| Mar 31, 2026 | 25,528.00 |
| Dec 31, 2025 | -53,292.00 |
| Dec 31, 2025 | -53,292.00 |
| Sep 30, 2025 | 102,010.00 |
| Sep 30, 2025 | 102,010.00 |
| Jun 30, 2025 | -59,457.00 |
| Jun 30, 2025 | -59,457.00 |
| Mar 31, 2025 | 20,520.00 |
| Mar 31, 2025 | 20,520.00 |
| Dec 31, 2024 | 12,853.00 |
| Dec 31, 2024 | 12,853.00 |
| Sep 30, 2024 | 22,727.00 |
| Sep 30, 2024 | 22,727.00 |
| Jun 30, 2024 | -172,638.00 |
| Jun 30, 2024 | -172,638.00 |
| Mar 31, 2024 | -18,494.00 |
| Mar 31, 2024 | -18,494.00 |